Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
03692 HANSOH PHARMA
RTNominal down19.560 -0.440 (-2.200%)
Others

04/06/2021 17:36

Hansoh Pharma (03692) gets drug registration approval

[ET Net News Agency, 4 June 2021] Hansoh Pharmaceutical Group Company Limited (03692)
said "Erlotinib Hydrochloride Tablets" developed by Jiangsu Hansoh Pharmaceutical Group
Co., Ltd., a subsidiary of the company, has been granted drug registration approval by the
National Medical Products Administration of the People's Republic of China.
The product is an oncology drug indicated for the treatment of patients with locally
advanced or late-stage metastatic non-small cell lung cancer (NSCLC) whose tumours have
epidermal growth factor receptor (EGFR) sensitizing mutations, and receiving first-line
treatment, maintenance treatment, or second or greater line treatment after progression at
least one prior chemotherapy regimen. (RC)

Back to Others

Remark: Real time quote last updated: 24/09/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.